

Appendix 6. References 19 RCTs included in systematic reviews

- Bang, Y.-J., Ruiz, E. Y., Van Cutsem, E., Lee, K.-W., Wyrwicz, L., Schenker, M., Alsina, M., Ryu, M.-H., Chung, H.-C., Evesque, L., Al-Batran, S.-E., Park, S. H., Lichinitser, M., Boku, N., Moehler, M. H., Hong, J., Xiong, H., Hallwachs, R., Conti, I., & Taieb, J. (2018). Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. *Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO*, 29(10), 2052–2060.
- Bramhall, S. R., Hallissey, M. T., Whiting, J., Scholefield, J., Tierney, G., Stuart, R. C., Hawkins, R. E., McCulloch, P., Maughan, T., Brown, P. D., Baillet, M., & Fielding, J. W. L. (2002). Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. *British Journal of Cancer*, 86(12), 1864–1870.
- Demetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., Badalamenti, G., Blackstein, M., Le Cesne, A., Schöffski, P., Maki, R. G., Bauer, S., Nguyen, B. B., Xu, J., Nishida, T., ... Casali, P. G. (2013). Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *The Lancet*, 381(9863), 295–302.
- Dutton, S. J., Ferry, D. R., Blazeby, J. M., Abbas, H., Dahle-Smith, A., Mansoor, W., Thompson, J., Harrison, M., Chatterjee, A., Falk, S., Garcia-Alonso, A., Fyfe, D. W., Hubner, R. A., Gamble, T., Peachey, L., Davoudianfar, M., Pearson, S. R., Julier, P., Jankowski, J., ... Petty, R. D. (2014). Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. *The Lancet Oncology*, 15(8), 894–904.
- Ford, H. E. R., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F. Y., Wadsley, J., Mansoor, W., Fyfe, D., Madhusudan, S., Middleton, G. W., Swinson, D., Falk, S., Chau, I., Cunningham, D., Kareclas, P., Cook, N., Blazeby, J. M., & Dunn, J. A. (2014). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *The Lancet Oncology*, 15(1), 78–86.
- Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., Melichar, B., Tehfe, M., Topuzov, E., Zalcborg, J. R., Chau, I., Campbell, W., Sivanandan, C., Pikiel, J., Koshiji, M., ... Tabernero, J. (2014). Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *The Lancet*, 383(9911), 31–39.
- Glimelius, B., Ekström, K., Hoffman, K., Graf, W., Sjöden, P.-O., Haglund, U., Svensson, C., Enander, L.-K., Linné, T., Sellsröm, H., & Heuman, R. (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. *Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO*, 8(2), 163–168.
- Kang, J. H., Lee, S. I., Lim, D. H., Park, K.-W., Oh, S. Y., Kwon, H.-C., Hwang, I. G., Lee, S.-C., Nam, E., Shin, D. B., Lee, J., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., & Park, S. H. (2012). Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone. *Journal of Clinical Oncology: JCO*, 30(13), 1513–1518.
- Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S.,

Muro, K., Kang, W. K., Yeh, K.-H., Yoshikawa, T., Oh, S. C., Bai, L.-Y., Tamura, T., Lee, K.-W., Hamamoto, Y., Kim, J. G., Chin, K., ... Chen, L.-T. (2017). Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*, 390(10111), 2461–2471.

Levard, H., Pouliquen, X., Hay, J.-M., Fingerhut, A., Langlois-Zantain, O., Huguier, M., Lozach, P., & Testart, J. (2003). 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma: A multicentre randomised controlled trial. *The European Journal of Surgery = Acta Chirurgica*, 164(11), 849–857.

Li, J., Qin, S., Xu, J., Guo, W., Xiong, J., Bai, Y., Sun, G., Yang, Y., Wang, L., Xu, N., Cheng, Y., Wang, Z., Zheng, L., Tao, M., Zhu, X., Ji, D., Liu, X., & Yu, H. (2013). Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial. *Journal of Clinical Oncology*, 31(26), 3219–3225.

Li, J., Qin, S., Xu, J., Xiong, J., Wu, C., Bai, Y., Liu, W., Tong, J., Liu, Y., Xu, R., Wang, Z., Wang, Q., Ouyang, X., Yang, Y., Ba, Y., Liang, J., Lin, X., Luo, D., Zheng, R., ... Yu, H. (2016). Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 34(13), 1448–1454.

Murad, A. M., Santiago, F. F., Petroianu, A., Rocha, P. R., Rodrigues, M. A., & Rausch, M. (1993). Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. *Cancer*, 72(1), 37–41.

Nicolaou, N., & Conlan, A. A. (1982). Cyclophosphamide, doxorubicin and celestin intubation for inoperable oesophageal carcinoma. *South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde*, 61(12), 428–431.

Ohtsu, A., Ajani, J. A., Bai, Y.-X., Bang, Y.-J., Chung, H.-C., Pan, H.-M., Sahmoud, T., Shen, L., Yeh, K.-H., Chin, K., Muro, K., Kim, Y. H., Ferry, D., Tebbutt, N. C., Al-Batran, S.-E., Smith, H., Costantini, C., Rizvi, S., Lebwohl, D., & Van Cutsem, E. (2013). Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. *Journal of Clinical Oncology*, 31(31), 3935–3943.

Pavlikis, N., Sjoquist, K. M., Tsobanis, E., Martin, A., Kang, Y.-K., Bang, Y.-J., O'Callaghan, C. J., Tebbutt, N. C., Rha, S. Y., Lee, J., Cho, J. Y., Lipton, L. R., Burnell, M. J., Alcindor, T., Strickland, A., Wong, M., Kim, J. W., Simes, J., Zalcborg, J. R., & Goldstein, D. (2015). INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results. *Journal of Clinical Oncology*, 33(3 suppl), 9–9.

Pyrhönen, S., Kuitunen, T., Nyandoto, P., & Kouri, M. (1995). Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. *British Journal of Cancer*, 71(3), 587–591.

Scheithauer W, Kornek G, Hejna M, Depisch D, Raderer M, Huber H. (1996). Palliative chemotherapy versus best supportive care in patients with metastatic gastric cancer: a randomized trial. *Annals of Hematology*, 73(Suppl 2), A181.

Thuss-Patience, P. C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., Dogan, Y., Gebauer, B., Schumacher, G., & Reichardt, P. (2011). Survival advantage for

irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *European Journal of Cancer*, 47(15), 2306–2314.